Indevus Pharma credits healthier drug sales for Q2 boost
Monday May 8, 4:37 pm ET Sales for two drugs helped boost Indevus Pharmaceuticals Inc.'s sales by 55 percent in the second quarter of 2006.

The Lexington, Mass.-based pharmaceutical company said revenue was $14.4 million, up from $9.3 million in the second quarter of 2005, primarily driven by sales and royalties of Sanctura, a treatment for overactive bladder, and by sales of Delatestryl, a testosterone replacement therapy.

Indevus (Nasdaq stock symbol IDEV) received $4.3 million on product sales of Sanctura to the company's partner, Esprit Pharma. Indevus received $1 million from product sales of Delatestryl and $2.2 million in sales-force subsidy.

"We are in the midst of one of the most active periods in the history of Indevus," said Glenn Cooper, Indevus chairman, CEO and president. The company completed enrollment in both Phase III clinical trials for Sanctura XR as well as our Phase II pagoclone trial for stuttering among other trials.

The company announced it has filed a new patent application with the U.S. Patent Office covering the use of pagoclone as a treatment for premature ejaculation and intends to initiate a proof-of-concept study during the summer.